S
Sofia Paul
Researcher at University of Texas MD Anderson Cancer Center
Publications - 4
Citations - 2367
Sofia Paul is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 1 publications receiving 2274 citations.
Papers
More filters
Journal ArticleDOI
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
Nasser H. Hanna,Frances A. Shepherd,Frank V. Fossella,José Rodrigues Pereira,Filippo de Marinis,Joachim von Pawel,Ulrich Gatzemeier,Thomas Chang Yao Tsao,Miklos Pless,Thomas Müller,Hong-Liang Lim,Christopher Desch,Klara Szondy,Radj Gervais,Shaharyar,Christian Manegold,Sofia Paul,Paolo Paoletti,Lawrence H. Einhorn,Paul A. Bunn +19 more
TL;DR: Treatment with pemetrexed resulted in clinically equivalent efficacy outcomes, but with significantly fewer side effects compared with docetaxel in the second-line treatment of patients with advanced NSCLC and should be considered a standard treatment option for second-liners when available.
Journal ArticleDOI
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy
Nasser H. Hanna,Frances A. Shepherd,Frank V. Fossella,José Rodrigues Pereira,Filippo de Marinis,Joachim von Pawel,Ulrich Gatzemeier,Thomas Chang-Yao Tsao,Miklos Pless,T. Muller,Hong-Liang Lim,Christopher E. Desch,Klara Szondy,Radj Gervais,Shaharyar,Christian Manegold,Sofia Paul,Paolo Paoletti,Lawrence H. Einhorn,Paul A. Bunn +19 more
TL;DR: In this paper , the efficacy and toxicity of pemetrexed versus docetaxel in patients with advanced non-small-cell lung cancer (NSCLC) previously treated with chemotherapy were compared.
Journal ArticleDOI
Tolerability and preliminary activity of the potent, selective, oral CDK7 inhibitor SY-5609 in combination with fulvestrant in patients with advanced hormone receptor-positive (HR+), HER2- breast cancer (BC).
Dejan Juric,Debra L. Richardson,Babar Bashir,M. Sharma,Kyriakos P. Papadopoulos,Sara Mathews,Graeme Hodgson,Susan Henry,Sofia Paul,Terence Hall,David A. Roth,Michael Kelly,Virginia M. Klimek +12 more
TL;DR: In this article , a Phase 1 study of SY-5609 + fulvestrant was conducted in patients with select advanced solid tumors (NCT04247126), where the authors evaluated the safety and tolerability of a single agent (SA) dose escalation using a 7 days on/7 days off (7/7) dosing schedule that optimized tolerability.
Journal ArticleDOI
Phase 1/1b study of SY-5609, a selective and potent CDK7 inhibitor, in advanced solid tumors and in 2L/3L pancreatic ductal adenocarcinoma (PDAC) in combination with gemcitabine +/- nab-paclitaxel.
Babar Bashir,M. Sharma,Dejan Juric,Kyriakos P. Papadopoulos,Erika Hamilton,Debra L. Richardson,Geoffrey I. Shapiro,Vaibhav Sahai,Niharika B. Mettu,O. Wainberg,Olatunji B. Alese,Tomislav Dragovich,Graeme Hodgson,Susan Henry,Terence Hall,Sofia Paul,David A. Roth,Michael Kelly,Virginia M. Klimek +18 more
TL;DR: In this paper , the authors presented data from the ongoing SA dose escalation and SY-5609 + gem +/- nab-paclitaxel (np) safety lead-ins (SLIs).